Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
Information source: University of Rochester
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Metabolic Syndrome
Intervention: Atorvastatin (Drug); Placebo (Other)
Phase: Phase 1/Phase 2
Status: Active, not recruiting
Sponsored by: University of Rochester Official(s) and/or principal investigator(s): Gladys P Velarde, MD, Principal Investigator, Affiliation: University of Rochester
Summary
Little is known regarding the association of individual components of the metabolic syndrome
(MBS) and prothrombotic, inflammatory and preclinical cardiac structural and functional
markers in women with this syndrome. Less is known about adequate treatment as the
pathological mechanism of this syndrome is not well understood.
The purpose of this study is two fold;
1. To determine basic differences in biochemical and cardiovascular structural markers in
women with and those without MBS and their association with the individual components
of MBS.
2. To determine the impact of atorvastatin to lower the risk factors of Metabolic
Syndrome. Atorvastatin is one of the most effective drugs approved by the United
States Food and Drug Administration (FDA) for the treatment of high cholesterol. It
belongs to a class of drugs called statins and its role in primary prevention is still
unclear. Thus this population seems to be an ideal group that may benefit from this
intervention.
Clinical Details
Official title: Interactions of Thrombogenic, Lipogenic, and Inflammatory Markers in Women With the Metabolic Syndrome - Effect of Atorvastatin
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Basic differences in cardio-metabolic markers in women with vs. those without the metabolic syndrome and impact of atorvastatin on these markers.
Detailed description:
The first phase of the study is an observational phase as previously described. The second
phase was a prospective evaluation of the effect of a well known "statin" drug (Liptor) on
different biochemical factors measured in the blood. The eligible study participants had
blood work done upon enrollment and if criteria was met(according to the Adult Treatment
Panel III), they were given dietary counseling (NYHA - New York Heart Association Step 1
diet) as a lead in phase. Lab work was repeated at 3 weeks to evaluate the impact of the
diet and if participant's profile still met criteria for MBS,randomization for either
atorvastatin (Liptor) 80mg or placebo (sugar pill) for 12 weeks took place.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Women between the ages of 18-75 with Metabolic syndrome
- Abdominal circumference > 35 in
- Hypertriglyceridemia > 150mg/dl
- HDL <50
- Blood Pressure >130/85
- Fasting Glucose >100
Exclusion Criteria:
- Pregnant or planning to become pregnant in the next 6-12 months
- Receiving lipid-lowing drugs
- Obstructive hepatobiliary disease or serious hepatic disease
- Diabetes, cardiovascular disease (CVD), hypothyroidism, active infection, cancer,
recent surgery
- Fulfill criteria to receive statin based on LDL levels, risk factors, and
Framingham risk scoring outlined on ATP111/NCEP 111 recommendations
- Documented allergic reaction to statin in past
- unexplained elevation in creatinine kinase levels > 3 times upper limit
Locations and Contacts
University of Rochester Medical Center, Rochester, New York 14642, United States
Additional Information
Starting date: November 2004
Last updated: February 7, 2013
|